These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 12186845)

  • 21. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection.
    Guiducci C; Vicari AP; Sangaletti S; Trinchieri G; Colombo MP
    Cancer Res; 2005 Apr; 65(8):3437-46. PubMed ID: 15833879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor ablation plus co-administration of CpG and saponin adjuvants affects IL-1 production and multifunctional T cell numbers in tumor draining lymph nodes.
    Raaijmakers TK; van den Bijgaart RJE; den Brok MH; Wassink M; de Graaf A; Wagenaars JA; Nierkens S; Ansems M; Scheffer GJ; Adema GJ
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccination with tumor peptide in CpG adjuvant protects via IFN-gamma-dependent CD4 cell immunity.
    Stern BV; Boehm BO; Tary-Lehmann M
    J Immunol; 2002 Jun; 168(12):6099-105. PubMed ID: 12055220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells.
    Hartmann G; Weiner GJ; Krieg AM
    Proc Natl Acad Sci U S A; 1999 Aug; 96(16):9305-10. PubMed ID: 10430938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences.
    Duramad O; Fearon KL; Chan JH; Kanzler H; Marshall JD; Coffman RL; Barrat FJ
    Blood; 2003 Dec; 102(13):4487-92. PubMed ID: 12946990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.
    Chagnon F; Tanguay S; Ozdal OL; Guan M; Ozen ZZ; Ripeau JS; Chevrette M; Elhilali MM; Thompson-Snipes LA
    Clin Cancer Res; 2005 Feb; 11(3):1302-11. PubMed ID: 15709202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of tumor-specific acquired immunity against already established tumors by selective stimulation of innate DEC-205(+) dendritic cells.
    Moriya K; Wakabayashi A; Shimizu M; Tamura H; Dan K; Takahashi H
    Cancer Immunol Immunother; 2010 Jul; 59(7):1083-95. PubMed ID: 20221597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Species-dependent role of type I IFNs and IL-12 in the CTL response induced by humanized CpG complexed with β-glucan.
    Kobiyama K; Temizoz B; Kanuma T; Ozasa K; Momota M; Yamamoto T; Aoshi T; Kuroda E; Ishii KJ
    Eur J Immunol; 2016 May; 46(5):1142-51. PubMed ID: 26786557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses.
    Murphy WJ; Welniak L; Back T; Hixon J; Subleski J; Seki N; Wigginton JM; Wilson SE; Blazar BR; Malyguine AM; Sayers TJ; Wiltrout RH
    J Immunol; 2003 Mar; 170(5):2727-33. PubMed ID: 12594303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancement of antigen-presenting ability of B lymphoma cells by immunostimulatory CpG-oligonucleotides and anti-CD40 antibody.
    Chen W; Yu Y; Shao C; Zhang M; Wang W; Zhang L; Cao X
    Immunol Lett; 2001 May; 77(1):17-23. PubMed ID: 11348665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modification of anti-tumor immunity by tolerogenic dendritic cells.
    Chen L; Hasni MS; Jondal M; Yakimchuk K
    Autoimmunity; 2017 Sep; 50(6):370-376. PubMed ID: 28675711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL-2 is required for the activation of memory CD8+ T cells via antigen cross-presentation.
    Blachère NE; Morris HK; Braun D; Saklani H; Di Santo JP; Darnell RB; Albert ML
    J Immunol; 2006 Jun; 176(12):7288-300. PubMed ID: 16751372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.
    Roda JM; Parihar R; Carson WE
    J Immunol; 2005 Aug; 175(3):1619-27. PubMed ID: 16034101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipopolysaccharide modulation of dendritic cells is insufficient to mature dendritic cells to generate CTLs from naive polyclonal CD8+ T cells in vitro, whereas CD40 ligation is essential.
    Kelleher M; Beverley PC
    J Immunol; 2001 Dec; 167(11):6247-55. PubMed ID: 11714787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CpG-DNA aided cross-priming by cross-presenting B cells.
    Heit A; Huster KM; Schmitz F; Schiemann M; Busch DH; Wagner H
    J Immunol; 2004 Feb; 172(3):1501-7. PubMed ID: 14734727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses.
    Dercamp C; Chemin K; Caux C; Trinchieri G; Vicari AP
    Cancer Res; 2005 Sep; 65(18):8479-86. PubMed ID: 16166328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvants LT-K63 and CpG enhance the activation of dendritic cells in neonatal mice.
    Hannesdottir SG; Olafsdottir TA; Giudice GD; Jonsdottir I
    Scand J Immunol; 2008 Nov; 68(5):469-75. PubMed ID: 18946928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vitamin C treatment of mouse bone marrow-derived dendritic cells enhanced CD8(+) memory T cell production capacity of these cells in vivo.
    Jeong YJ; Kim JH; Hong JM; Kang JS; Kim HR; Lee WJ; Hwang YI
    Immunobiology; 2014 Jul; 219(7):554-64. PubMed ID: 24698552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
    Datta N; Mukherjee S; Das L; Das PK
    Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.